Genome maintenance in retinoblastoma: Implications for therapeutic vulnerabilities (Review)
- Authors:
- Chunsik Lee
- Jong Kyong Kim
-
Affiliations: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat‑sen University, Guangzhou, Guangdong 510060, P.R. China - Published online on: April 29, 2022 https://doi.org/10.3892/ol.2022.13312
- Article Number: 192
-
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F and Gallie BL: Retinoblastoma. Nat Rev Dis Primers. 1:150212015. View Article : Google Scholar : PubMed/NCBI | |
|
Benavente CA and Dyer MA: Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562. 2015. View Article : Google Scholar | |
|
Theriault BL, Dimaras H, Gallie BL and Corson TW: The genomic landscape of retinoblastoma: A review. Clin Exp Ophthalmol. 42:33–52. 2014. View Article : Google Scholar | |
|
Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dick FA, Goodrich DW, Sage J and Dyson NJ: Non-canonical functions of the RB protein in cancer. Nat Rev Cancer. 18:442–451. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Talluri S and Dick FA: Regulation of transcription and chromatin structure by pRB: Here, there and everywhere. Cell Cycle. 11:3189–3198. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Uchida C: Roles of pRB in the regulation of nucleosome and chromatin structures. Biomed Res Int. 2016:59597212016. View Article : Google Scholar | |
|
Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK and Goodrich DW: Cell cycle and beyond: Exploiting New RB1 controlled mechanisms for cancer therapy. Trends Cancer. 5:308–324. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Linn P, Kohno S, Sheng J, Kulathunga N, Yu H, Zhang Z, Voon D, Watanabe Y and Takahashi C: Targeting RB1 loss in cancers. Cancers (Basel). 13:37372021. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar | |
|
Velez-Cruz R and Johnson DG: The Retinoblastoma (RB) tumor suppressor: Pushing back against genome instability on multiple fronts. Int J Mol Sci. 18:17762017. View Article : Google Scholar | |
|
Cook R, Zoumpoulidou G, Luczynski MT, Rieger S, Moquet J, Spanswick VJ, Hartley JA, Rothkamm K, Huang PH and Mittnacht S: Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining. Cell Rep. 10:2006–2018. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Velez-Cruz R, Manickavinayaham S, Biswas AK, Clary RW, Premkumar T, Cole F and Johnson DG: RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes Dev. 30:2500–2512. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Manickavinayaham S, Velez-Cruz R, Biswas AK, Chen J, Guo R and Johnson DG: The E2F1 transcription factor and RB tumor suppressor moonlight as DNA repair factors. Cell Cycle. 19:2260–2269. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, Bensimon A, Zamir G, Shewach DS and Kerem B: Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 145:435–446. 2011. View Article : Google Scholar | |
|
Longworth MS, Herr A, Ji JY and Dyson NJ: RBF1 promotes chromatin condensation through a conserved interaction with the Condensin II protein dCAP-D3. Genes Dev. 22:1011–1024. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Manning AL, Longworth MS and Dyson NJ: Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 24:1364–1376. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Manning AL, Yazinski SA, Nicolay B, Bryll A, Zou L and Dyson NJ: Suppression of genome instability in pRB-deficient cells by enhancement of chromosome cohesion. Mol Cell. 53:993–1004. 2014. View Article : Google Scholar | |
|
Coschi CH, Ishak CA, Gallo D, Marshall A, Talluri S, Wang J, Cecchini MJ, Martens AL, Percy V, Welch I, et al: Haploinsufficiency of an RB-E2F1-Condensin II complex leads to aberrant replication and aneuploidy. Cancer Discov. 4:840–853. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Coschi CH, Martens AL, Ritchie K, Francis SM, Chakrabarti S, Berube NG and Dick FA: Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive. Genes Dev. 24:1351–1363. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ishak CA, Marshall AE, Passos DT, White CR, Kim SJ, Cecchini MJ, Ferwati S, MacDonald WA, Howlett CJ, Welch ID, et al: An RB-EZH2 complex mediates silencing of repetitive DNA Sequences. Mol Cell. 64:1074–1087. 2016. View Article : Google Scholar | |
|
Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE, Eguia R, Dean DC, Esteller M, Jenuwein T and Blasco MA: Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol. 7:420–428. 2005. View Article : Google Scholar | |
|
Isaac CE, Francis SM, Martens AL, Julian LM, Seifried LA, Erdmann N, Binne UK, Harrington L, Sicinski P, Berube NG, et al: The retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol. 26:3659–3671. 2006. View Article : Google Scholar | |
|
Montoya-Durango DE, Ramos KA, Bojang P, Ruiz L, Ramos IN and Ramos KS: LINE-1 silencing by retinoblastoma proteins is effected through the nucleosomal and remodeling deacetylase multiprotein complex. BMC Cancer. 16:382016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, et al: A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 481:329–334. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, et al: RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget. 5:438–450. 2014. View Article : Google Scholar | |
|
Davies HR, Broad KD, Onadim Z, Price EA, Zou X, Sheriff I, Karaa EK, Scheimberg I, Reddy MA, Sagoo MS, et al: Whole-Genome sequencing of retinoblastoma reveals the diversity of rearrangements disrupting RB1 and uncovers a treatment-related mutational signature. Cancers (Basel). 13:7542021. View Article : Google Scholar : PubMed/NCBI | |
|
Kooi IE, Mol BM, Massink MP, Ameziane N, Meijers-Heijboer H, Dommering CJ, van Mil SE, de Vries Y, van der Hout AH, Kaspers GJ, et al: Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. Sci Rep. 6:252642016. View Article : Google Scholar : PubMed/NCBI | |
|
Afshar AR, Pekmezci M, Bloomer MM, Cadenas NJ, Stevers M, Banerjee A, Roy R, Olshen AB, Van Ziffle J, Onodera C, et al: Next-Generation sequencing of retinoblastoma identifies pathogenic alterations beyond RB1 inactivation that correlate with aggressive histopathologic features. Ophthalmology. 127:804–813. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Francis JH, Richards AL, Mandelker DL, Berger MF, Walsh MF, Dunkel IJ, Donoghue MTA and Abramson DH: Molecular changes in retinoblastoma beyond RB1: Findings from next-generation sequencing. Cancers (Basel). 13:1492021. View Article : Google Scholar | |
|
Mendonca V, Evangelista AC, P Matta B, M Moreira MÂ, Faria P, Lucena E and Seuanez HN: Molecular alterations in retinoblastoma beyond RB1. Exp Eye Res. 211:1087532021. View Article : Google Scholar : PubMed/NCBI | |
|
Corson TW and Gallie BL: One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 46:617–634. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Ottaviani D, Sefta M, Desbrousses C, Chapeaublanc E, Aschero R, Sirab N, Lubieniecki F, Lamas G, Tonon L, et al: A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nat Commun. 12:55782021. View Article : Google Scholar : PubMed/NCBI | |
|
Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, et al: The landscape of genomic alterations across childhood cancers. Nature. 555:321–327. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S and Stratton MR: Clock-like mutational processes in human somatic cells. Nat Genet. 47:1402–1407. 2015. View Article : Google Scholar | |
|
Polski A, Xu L, Prabakar RK, Gai X, Kim JW, Shah R, Jubran R, Kuhn P, Cobrinik D, Hicks J and Berry JL: Variability in retinoblastoma genome stability is driven by age and not heritability. Genes Chromosomes Cancer. 59:584–590. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, Toguchida J and Sasaki MS: Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett. 106:75–82. 1996. View Article : Google Scholar | |
|
Kondo Y, Kondo S, Liu J, Haqqi T, Barnett GH and Barna BP: Involvement of p53 and WAF1/CIP1 in gamma-irradiation-induced apoptosis of retinoblastoma cells. Exp Cell Res. 236:51–56. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, Almeida D, Liu A, Jhanwar SC, Abramson DH and Cobrinik D: Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell. 137:1018–1031. 2009. View Article : Google Scholar | |
|
Xu XL, Singh HP, Wang L, Qi DL, Poulos BK, Abramson DH, Jhanwar SC and Cobrinik D: Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature. 514:385–388. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al: Inactivation of the p53 pathway in retinoblastoma. Nature. 444:61–66. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR and Kumar A: Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics. 90:344–353. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ganguly A and Shields CL: Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis. 16:1292–1303. 2010.PubMed/NCBI | |
|
Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M, Peet AC and McConville CM: Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer. 109:512–525. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rajasekaran S, Nagarajha Selvan LD, Dotts K, Kumar R, Rishi P, Khetan V, Bisht M, Sivaraman K, Krishnakumar S, Sahoo D, et al: Non-coding and coding transcriptional profiles are significantly altered in pediatric retinoblastoma tumors. Front Oncol. 9:2212019. View Article : Google Scholar | |
|
Aubry A, Pearson JD, Huang K, Livne-Bar I, Ahmad M, Jagadeesan M, Khetan V, Ketela T, Brown KR, Yu T, et al: Functional genomics identifies new synergistic therapies for retinoblastoma. Oncogene. 39:5338–5357. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, et al: Loss of the retinoblastoma tumor suppressor: Differential action on transcriptional programs related to cell cycle control and immune function. Oncogene. 26:6307–6318. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, et al: RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology. 133:976–984. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL, Ishida S, West M and Nevins JR: Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res. 63:3716–3723. 2003.PubMed/NCBI | |
|
Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bracken AP, Ciro M, Cocito A and Helin K: E2F target genes: Unraveling the biology. Trends Biochem Sci. 29:409–417. 2004. View Article : Google Scholar | |
|
Mun JY, Baek SW, Park WY, Kim WT, Kim SK, Roh YG, Jeong MS, Yang GE, Lee JH, Chung JW, et al: E2F1 promotes progression of bladder cancer by modulating RAD54L involved in homologous recombination repair. Int J Mol Sci. 21:90252020. View Article : Google Scholar | |
|
Sakthivel KM and Hariharan S: Regulatory players of DNA damage repair mechanisms: Role in cancer chemoresistance. Biomed Pharmacother. 93:1238–1245. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hosoya N and Miyagawa K: Targeting DNA damage response in cancer therapy. Cancer Sci. 105:370–388. 2014. View Article : Google Scholar | |
|
O'Connor MJ: Targeting the DNA damage response in cancer. Mol Cell. 60:547–560. 2015. View Article : Google Scholar | |
|
Jeggo PA and Downs JA: Roles of chromatin remodellers in DNA double strand break repair. Exp Cell Res. 329:69–77. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee C and Kim JK: Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications. J Cell Physiol. 236:2318–2332. 2021. View Article : Google Scholar | |
|
Bronner C, Krifa M and Mousli M: Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol. 86:1643–1649. 2013. View Article : Google Scholar | |
|
Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mousli M and Bronner C: Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. J Exp Clin Cancer Res. 35:1742016. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Y, Paramasivam M, Ghosal G, Chen D, Shen X, Huang Y, Akhter S, Legerski R, Chen J, Seidman MM, et al: UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold. Cell Rep. 10:1957–1966. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liang CC, Zhan B, Yoshikawa Y, Haas W, Gygi SP and Cohn MA: UHRF1 is a sensor for DNA interstrand crosslinks and recruits FANCD2 to initiate the Fanconi anemia pathway. Cell Rep. 10:1947–1956. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Liu H, Chen Y, Yang X, Wang P, Liu T, Deng M, Qin B, Correia C, Lee S, et al: A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun. 7:102012016. View Article : Google Scholar : PubMed/NCBI | |
|
Mancini M, Magnani E, Macchi F and Bonapace IM: The multi-functionality of UHRF1: Epigenome maintenance and preservation of genome integrity. Nucleic Acids Res. 49:6053–6068. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Muto M, Kanari Y, Kubo E, Takabe T, Kurihara T, Fujimori A and Tatsumi K: Targeted disruption of Np95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks. J Biol Chem. 277:34549–34555. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
He H, Lee C and Kim JK: UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4. Cell Death Dis. 9:1642018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JK, Kan G, Mao Y, Wu Z, Tan X, He H and Lee C: UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis. Mol Oncol. 14:329–346. 2020. View Article : Google Scholar | |
|
Sharma V, Collins LB, Chen TH, Herr N, Takeda S, Sun W, Swenberg JA and Nakamura J: Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations. Oncotarget. 7:25377–25390. 2016. View Article : Google Scholar | |
|
Karanjawala ZE, Murphy N, Hinton DR, Hsieh CL and Lieber MR: Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Curr Biol. 12:397–402. 2002. View Article : Google Scholar | |
|
Mao Y, Sun Y, Wu Z, Zheng J, Zhang J, Zeng J, Lee C and Kim JK: Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy. Cell Death Dis. 12:11412021. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K and Zhang Y: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol. 12:1052–1058. 2002. View Article : Google Scholar | |
|
Wood K, Tellier M and Murphy S: DOT1L and H3K79 methylation in transcription and genomic stability. Biomolecules. 8:112018. View Article : Google Scholar | |
|
Wakeman TP, Wang Q, Feng J and Wang XF: Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J. 31:2169–2181. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, Ubelmesser N, Mansour WY, Eggert J, Spitzner M, et al: The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 11:42019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Deng L, Song Y and Redell M: DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One. 9:e982702014. View Article : Google Scholar : PubMed/NCBI | |
|
Chau KY, Manfioletti G, Cheung-Chau KW, Fusco A, Dhomen N, Sowden JC, Sasabe T, Mukai S and Ono SJ: Derepression of HMGA2 gene expression in retinoblastoma is associated with cell proliferation. Mol Med. 9:154–165. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Palmieri D, Valentino T, D'Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M and Fusco A: HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene. 30:3024–3035. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Natarajan S, Hombach-Klonisch S, Droge P and Klonisch T: HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia. 15:263–280. 2013. View Article : Google Scholar | |
|
Nalini V, Deepa PR, Raguraman R, Khetan V, Reddy MA and Krishnakumar S: Targeting HMGA2 in Retinoblastoma Cells in vitro using the aptamer strategy. Ocul Oncol Pathol. 2:262–269. 2016. View Article : Google Scholar | |
|
Kollarovic G, Topping CE, Shaw EP and Chambers AL: The human HELLS chromatin remodelling protein promotes end resection to facilitate homologous recombination and contributes to DSB repair within heterochromatin. Nucleic Acids Res. 48:1872–1885. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Costelloe T, Louge R, Tomimatsu N, Mukherjee B, Martini E, Khadaroo B, Dubois K, Wiegant WW, Thierry A, Burma S, et al: The yeast Fun30 and human SMARCAD1 chromatin remodellers promote DNA end resection. Nature. 489:581–584. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zocchi L, Mehta A, Wu SC, Wu J, Gu Y, Wang J, Suh S, Spitale RC and Benavente CA: Chromatin remodeling protein HELLS is critical for retinoblastoma tumor initiation and progression. Oncogenesis. 9:252020. View Article : Google Scholar : PubMed/NCBI | |
|
Manning AL and Dyson NJ: RB: Mitotic implications of a tumour suppressor. Nat Rev Cancer. 12:220–226. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pappas L, Xu XL, Abramson DH and Jhanwar SC: Genomic instability and proliferation/survival pathways in RB1-deficient malignancies. Adv Biol Regul. 64:20–32. 2017. View Article : Google Scholar | |
|
Salehi F, Kovacs K, Scheithauer BW, Lloyd RV and Cusimano M: Pituitary tumor-transforming gene in endocrine and other neoplasms: A review and update. Endocr Relat Cancer. 15:721–743. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Holland AJ and Cleveland DW: Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 10:478–487. 2009. View Article : Google Scholar | |
|
Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, et al: Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 9:248–263. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, et al: Cells lacking the RB1 tumor suppressor gene are hyperdependent on Aurora B kinase for survival. Cancer Discov. 9:230–247. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN and Rogister B: The functional diversity of Aurora kinases: A comprehensive review. Cell Div. 13:72018. View Article : Google Scholar : PubMed/NCBI | |
|
Borah NA, Sradhanjali S, Barik MR, Jha A, Tripathy D, Kaliki S, Rath S, Raghav SK, Patnaik S, Mittal R and Reddy MM: Aurora Kinase B expression, its regulation and therapeutic targeting in human retinoblastoma. Invest Ophthalmol Vis Sci. 62:162021. View Article : Google Scholar | |
|
Singh L, Pushker N, Sen S, Singh MK, Chauhan FA and Kashyap S: Prognostic significance of polo-like kinases in retinoblastoma: Correlation with patient outcome, clinical and histopathological parameters. Clin Exp Ophthalmol. 43:550–557. 2015. View Article : Google Scholar | |
|
Ma H, Nie C, Chen Y, Li J, Xie Y, Tang Z, Gao Y, Ai S, Mao Y, Sun Q and Lu R: Therapeutic Targeting PLK1 by ON-01910.Na is effective in local treatment of retinoblastoma. Oncol Res. 28:745–761. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Takaki T, Trenz K, Costanzo V and Petronczki M: Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 20:650–660. 2008. View Article : Google Scholar | |
|
Sun J, Xi HY, Shao Q and Liu QH: Biomarkers in retinoblastoma. Int J Ophthalmol. 13:325–341. 2020. View Article : Google Scholar | |
|
Chai P, Jia R, Li Y, Zhou C, Gu X, Yang L, Shi H, Tian H, Lin H, Yu J, et al: Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. Prog Retin Eye Res. Dec 1–2021.(Epub ahead of print). View Article : Google Scholar | |
|
Chan HS, Gallie BL, Munier FL and Beck Popovic M: Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 1855–63. (viii)2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, Antoneli CB, Greenwald M, Haik BG, Leal CA, et al: Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology. 114:1378–1383. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL and Chan HS: Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 121:1120–1124. 2003. View Article : Google Scholar | |
|
Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR, Manji J, et al: Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 12:70642021. View Article : Google Scholar : PubMed/NCBI | |
|
Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, et al: Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des. 80:971–980. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Waters NJ: Preclinical Pharmacokinetics and pharmacodynamics of pinometostat (EPZ-5676), a First-in-Class, small Molecule S-Adenosyl methionine competitive inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet. 42:891–901. 2017. View Article : Google Scholar | |
|
Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, et al: The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 131:2661–2669. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, Jabbour P and Shields JA: Intra-arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma. Ophthalmology. 121:1453–1460. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP and Beck-Popovic M: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol. 96:1078–1083. 2012. View Article : Google Scholar | |
|
Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A and Roohipoor R: Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 132:936–941. 2014. View Article : Google Scholar | |
|
Lee JE and Kim MY: Cancer epigenetics: Past, present and future. Semin Cancer Biol. Mar 31–2021.(Epub ahead of print). View Article : Google Scholar | |
|
He L and Lomberk G: Collateral Victim or Rescue Worker?-The role of histone methyltransferases in DNA damage repair and their targeting for therapeutic opportunities in cancer. Front Cell Dev Biol. 9:7351072021. View Article : Google Scholar | |
|
Unoki M, Nishidate T and Nakamura Y: ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesan A, Arimondo PB, Rots MG, Jeronimo C and Berdasco M: The timeline of epigenetic drug discovery: From reality to dreams. Clin Epigenetics. 11:1742019. View Article : Google Scholar : PubMed/NCBI | |
|
Chun AW, Cosenza SC, Taft DR and Maniar M: Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol. 65:177–186. 2009. View Article : Google Scholar | |
|
Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF III, Benisovich V, Navada S, et al: Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 3:323–338. 2013.PubMed/NCBI | |
|
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, et al: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 26:1923–1929. 2015. View Article : Google Scholar | |
|
Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, et al: Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 20:1656–1665. 2014. View Article : Google Scholar : PubMed/NCBI |
